GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.

摘要: This study was conducted to evaluate the effectiveness and tolerance of GDP (gemcitabine, dexamethasone, cisplatin) regimen in patients with newly diagnosed stage IV relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type (ENKTL).The enrolled 41 ENKTL who received at Cancer Hospital, Chinese Academy Medical Sciences Peking Union College between January 2008 2015.The disease status 15 26 patients. The median number cycles chemotherapy per patient 6 (range, 2-8 cycles). overall response rate complete-remission were 83.0% (34/41) 41.5% (17/41), respectively. After a follow-up 16.2 months, 1-year progression-free survival for whole cohort 54.5% 72.7%. Grade 3 4 adverse events included neutropenia (34.1%), thrombocytopenia (19.5%), anemia (14.6%).Our has suggested high efficacy low toxicity profile ENKTL.